---
document_datetime: 2024-01-17 11:00:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_en.pdf
document_name: anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6870575
conversion_datetime: 2025-12-26 21:10:21.665026
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number                    | (Invented) name                       | Strength    | Pharmaceutical Form         | Route of Administration   | Immediate Packaging         | Pack size                 |
|-----------------------------------|---------------------------------------|-------------|-----------------------------|---------------------------|-----------------------------|---------------------------|
| EU/1/17/1256/001 EU/1/17/1256/002 | Anagrelide Viatris Anagrelide Viatris | 0.5 mg 1 mg | Capsule, hard Capsule, hard | Oral use Oral use         | bottle (HDPE) bottle (HDPE) | 100 capsules 100 capsules |